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Atherosclerotic cardiovascular disease (CVD) represents a significant health 
issue in the present and future worldwide populations, thus implying a crucial 
role in their risk assessment in primary and secondary prevention. Among the 
classical risk factors, lipids and lipoproteins serum concentrations are used to 
estimate the risk of CVD and guide therapeutic decision-making. In the 
present study, we focused on the prognostic value of the lipoprotein (a) 
[Lp(a)], a < 70 nm diameter low-density lipoprotein (LDL) that can freely 
flux across the endothelial vascular barrier and settle within the arterial wall 
[1]. Both pathophysiological and prognostic values of Lp(a) remain unclear.  
Given his structural similarity to plasminogen and the oxidized phospholipid 
load,  Lp(a) shows pro-coagulant and pro-inflammatory effects [2]. Lifelong 
exposure to higher Lp(a) levels were strongly and causally associated with an 
increased risk of atherosclerotic cardiovascular disease in Mendelian 
randomization studies [3, 4], but observational studies show a weaker 
association compared with LDL concentration and unclear cut-off [5, 6].  In 
the present study, the prognostic value of Lp(a) and its correlation with 
intraplaque features were assessed in patients with severe carotid artery 
stenosis undergoing endarterectomy (n=180). The cut-off value of 10 mg/dL 
for serum Lp(a) was selected to predict 24-month follow-up acute coronary 
syndrome (ACS). Besides, the association between serum Lp(a) and 
intraplaque lipids, collagen, inflammatory and vascular cells was assessed. 
Serum Lp(a) levels were measured by nephelometric assay. Patients with high 
Lp(a) had similar comorbidities, medications and laboratory parameters as 
compared to low Lp(a) levels. At 24-month follow-up, patients with high 
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Lp(a) had more ACS as compared to low levels. Histological parameters 
within plaques were comparable in the study groups. No significant 
correlation between Lp(a) serum levels and intraplaque parameters was 
found, except for a weak positive association with smooth muscle cells in 
upstream plaque portions. When adjusted for gender, presence of 
dyslipidaemia and chronic coronary artery disease, Lp(a) ≥10 mg/dL 
remained predictive for ACS. In conclusion, Lp(a) determination could be 
useful to predict ACS in patients with severe carotid stenosis. 
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GENERALITIES 
Lp (a) is a low-density lipoprotein synthesised and secreted by the liver and 
comprises a lipid core of LDL cholesterol and apolipoprotein B-100, linked 
by a single interchain disulphide bridge to a unique glycoprotein, apoprotein 
(a) [7, 8]. The physiological function of Lp (a) is unclear, but several 
observational studies, including meta-analyses and genomic investigations, 
suggest that high Lp (a) concentrations are associated with myocardial 
infarction, stroke and calcific aortic valve stenosis [9-11]. The most recent 
international guidelines recommend considering circulating Lp (a) 
measurement in people with high CVD risk (i.e. patients with ≥ 10% of 10-
year risk of a fatal cardiovascular event, patients personal or a family history 
of premature CVD, familial hypercholesterolemia or recurrent CVD despite 
optimal lipid-lowering treatment) as well as in patients who have an estimated 
10-year risk that is close to the threshold between high and moderate risk, in 
order to provide significant improved risk reclassification under certain 
conditions that are not reflected by the SCORE system [12]. The cut-off value 
of serum Lp(a) associated with increased CVD risk was suggested at above 
50 mg/dL [13]. However, in a recent meta-analysis, including eleven 
secondary prevention studies, the prognostic cut-off value of Lp (a) in 
established CVD remains unclear, and no threshold risk effect was found 
[13]. Moreover, data in secondary prevention populations are limited to 
heterogeneous trials, raising questions regarding the value of Lp (a) as a 






This study aimed to explore the predictive role of Lp (a) for the development 
of ACS  and his relationship with atherosclerotic plaque components in a 
cohort of high-risk patients with advanced atherosclerosis (i.e. severe carotid 
artery stenosis undergoing carotid endarterectomy [CEA]). 
A research article from this project has been published in the European 
Journal of Clinical Investigation 2018 Mar;48(3) doi: 10.1111/eci.12888). 
 
Materials and methods 
This is a pilot sub-study of a previously published cohort of patients suffering 
from severe carotid artery stenosis undergoing CEA [14]. Briefly, between 
March 2008 and November 2012, we prospectively included 284 patients 
with severe extracranial high-grade internal carotid artery stenosis (defined 
as >70% luminal narrowing diagnosed at ultrasound Doppler), who 
underwent CEA at a single hospital (San Martino Hospital) in Genoa, Italy.  
Among the total cohort, only 180 samples were available for measurement of 
serum Lp(a) levels, as reported in Figure 1.  
All 180 patients were included in this sub-study analysis, acknowledging that 
24-month follow up information was available for only 150 patients (17% of 
















All patients underwent elective carotid endarterectomy according to the 
recommendations published by the North American Symptomatic Carotid 
Endarterectomy Trial (NASCET) [15], the European Carotid Surgery Trial 
(ECST) [16], and the Asymptomatic Carotid Surgery Trial (ACST) [17]. On 
total 180 patients enrolled, 136 patients were asymptomatic, while 44 were 
symptomatic for ischemic stroke (meaning they presented a first episode of 
ischemic stroke in the period between 30 and 10 days before CEA).  
Ischemic stroke was defined as ipsilateral focal neurological deficit of acute 
onset lasting >24 hours. The day before endarterectomy, blood samples were 
obtained by peripheral venipuncture at fasting state to collect both serum and 
plasma and to perform blood parameters. Internal carotid plaques were 
shortly processed (within 10 minutes on ice temperature) after CEA. All 
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atherosclerotic plaques were cut perpendicular to the long axis through the 
point of maximum stenosis to obtain two portions (upstream and downstream 
the blood flow). All patients were prospectively followed every six months 
with a clinical examination up to 24 months. Medications reported in Table 
1 were not modified in the two months before enrolment. Exclusion criteria 
were reported in previous publications from the same cohort of patients 
[14,18].  
Based on recent evidence, we assumed values of Lp(a) lower than 10 ng/ml 
as the threshold defining low risk of CVD [19, 20]. Therefore, patients were 
categorized low Lp(a) (<10 mg/dL, defined as controls) and high Lp(a) (≥10 
mg/dL, defined as cases).  
The Medical Ethics Committee of San Martino Hospital approved the study, 
and all participants provided written informed consent. The study was 
conducted in compliance with the Declaration of Helsinki.   
 
Study endpoints  
The primary end-point of the study was to determine whether high Lp(a) 
levels, would predict the occurrence of an ACS at 24-month follow-up after 
the CEA. The secondary endpoint was to determine the potential correlations 
between circulating Lp(a) and histological parameters of intraplaque 
inflammation in upstream and downstream portions of carotid plaques. Two 
independent investigators who were blinded to the biochemical and 
histological analyses adjudicated the study endpoints. Information was 
obtained during a check-up visit at 24 months and was further confirmed by 
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checking patients' medical file, mainly, targeting medical history relevant to 
the study endpoint. 
 
Detection of circulating molecules   
Serum C-reactive protein (CRP) levels were measured by colourimetric 
enzyme-linked immunosorbent assay (R&D Systems, Minneapolis, MN), 
following the manufacturer’s instructions. Lp(a) levels were determined in 
serum samples using a nephelometry assay  (Immage Immunchemie System, 
Beckmann Coulter, Italy) with a polyclonal antibody directed against the 
apoprotein(a)-domain of Lp(a) in an assay insensitive to apoprotein(a) 
isoforms. The limits of detection were 15.62 pg/mL for C-reactive protein and 
2 mg/dL for Lp(a). Mean intra- and interassay coefficients of variation were 
<8% for all markers. Glucose, triglycerides, total cholesterol, low-density 
lipoprotein cholesterol, high-density lipoprotein cholesterol, fibrinogen and 
d-dimer were routinely measured.  
  
Sirius Red staining for collagen content  
Eight sections per each portion separated by 105 μm from each other 
(upstream and downstream the blood flow) were rinsed with water and 
incubated with 0.1% Sirius red (Sigma Chemical Co) in saturated picric acid 
for 90 minutes. Sections were rinsed twice with 0.01 N HCl for 1 minute and 
then immersed in water. After dehydration with ethanol for 30 seconds and 
coverslipping, the sections were photographed with identical exposure 
settings each section under either conventional polychromatic or polarized 
light microscopy. Total collagen content was evaluated under polychromatic 
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light (Sirius red staining). Interstitial collagen subtypes were evaluated using 
polarized light illumination; under this condition, thicker Type I collagen 
fibres appeared orange or red, whereas thinner Type III collagen fibres were 
yellow or green [18]. Quantifications were performed with MetaMorph™ 6  
software. Data were calculated as percentages of the stained area on total 
lesion area.  
  
Oil Red O staining for intraplaque lipid content  
Eight sections separated by 105 μm from each other per each portion 
(upstream and downstream the blood flow) were incubated in 60% 
isopropanol for 2 minutes and then in Oil Red O solution for 20 minutes and 
rinsed in phosphate-buffered saline. Sections were then counterstained with 
Mayer’s hemalune solution and rinsed in distilled water. Quantifications were 
performed with MetaMorph™ 6 software. Data were calculated as 
percentages of the stained area on total lesion area.  
  
Immunostaining of carotid plaques  
Eight sections separated by 105 μm from each other per each portion 
(upstream and downstream the blood flow) were fixed in acetone at room 
temperature and immunostained with specific antibodies anti-human smooth 
muscle actin (smooth muscle cells [SMC], diluted: 1:100; Dako Corporation, 
Glostrup, Denmark), anti-human CD66b (neutrophils, diluted: 1:50; 
Beckman Coulter, Nyon Switzerland) anti-human CD68 (macrophages, 
diluted: 1:100; Dako Corporation) and anti-human matrix metalloproteinase 
(MMP)-9 (diluted 1:250; Southern Biotech, Birmingham AL). 
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Quantifications were performed using MetaMorph™ 6 software. Data were 
presented as cells/mm2 (neutrophils) or percentages of the stained area on 
total lesion area (other parameters). 
 
Statistical analyses   
Patient characteristics were described one day before endarterectomy (Table 
1). Categorical data are presented as relative and absolute frequencies. 
Continuous variables were expressed as median and interquartile range (IQR) 
as the normality assumption was not demonstrated.  
Intergroup comparisons were drawn by Fisher’s exact test and Mann-
Whitney U-test, as appropriate. Ranked Spearman correlation coefficients 
were performed to establish correlations between Lp(a) serum levels and 
inflammatory biomarkers in both upstream and downstream portions of 
atherosclerotic plaques. Kaplan-Meier analysis was performed to estimate 
cumulative ACS rate at follow-up and to calculate the corresponding risk 
difference according to the study groups. The effect of Lp(a) ≥10 mg/dL on 
the risk of the ACS was estimated by Cox proportional hazard models and 
expressed with hazard ratios (HR) and 95% CI. Multivariate analysis was 
performed adjusting for some classical risk factors for ACS, such as gender, 
dyslipidaemia and coronary artery disease (CAD), in order to obtain estimates 
of the HRs and to identify factors independently associated with the outcome. 
Values with p<0.05 (two-tailed) were considered significant. All analyses 






Patients’ characteristics   
Baseline demographic, clinical and biochemical characteristics, as well as 
medications of the patients according to the Lp(a) threshold value of 10 
mg/dL, are shown in Table 1. As potentially expected, patients with high 
Lp(a) levels at admission were more affected by chronic coronary artery 
disease (18.9 vs. 15.0%; p=0.021), higher d-dimer plasma levels (266.2 vs. 
179.4 μg/mL; p=0.003), as well as higher serum levels of fibrinogen (4.19 vs. 




































Patients with high and low serum levels of Lp(a) have a similar histological 
composition of carotid plaques  
 
When histological intraplaque parameters were assessed within different 
portions (upstream and downstream the blood flow) of carotid plaques, 
patients with high Lp(a) levels had similar lipid, collagen, SMC, macrophage, 
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Also, when assessing the potential association between Lp(a) levels and 
intraplaque parameters, only a weak positive association between SMC and 
Lp(a) levels was found in upstream regions (Table 3). Taken together, these 
results suggest that Lp(a) serum levels were not associated with histological 




















3.3 Serum levels of Lp(a) ≥10 mg/dL predict ACS at 24-month follow-up   
 
Based on a Kaplan-Meyer curve analysis, patients with Lp(a) serum levels 
≥10 mg/dL were shown to develop more ACS at 24-month follow-up as 
compared to low Lp(a) serum levels (12.5% vs 2.1%, Log Rank test: p=0.003, 







Importantly, Lp(a) serum levels ≥10 mg/dL were able to predict ACS at 24-
month follow-up (HR: 6.490 [95% CI: 1.550-27.160]; p=0.010) (Table 4). 
This association remained statistically significant after adjustment for known 
cardiovascular risk factors, such as male gender, dyslipidemia and chronic 







The main finding of this pilot analysis is that in patients with severe carotid 
artery stenosis (advanced atherosclerosis), Lp(a) serum levels ≥10 mg/dL 
were associated with an increased risk of developing an ACS. Circulating 
concentrations of Lp(a) were reported to range from <0.1 mg/dL to more than 
200 mg/dL in healthy individuals [7], independently of age and gender. It is 
estimated that about 70% of the variance of Lp(a) concentrations are 
genetically set, mainly by the LPA gene, which determines both the synthetic 
hepatic rate and the size of the apopoprotein(a) within Lp(a) [21]. Once 
released in the systemic circulation, elevated Lp(a) levels have been 
associated with CVD risk [22], suggesting that a genetic predisposition to 
high Lp(a) levels might significantly impact on accelerated atherogenesis 
[23]. Since this observation was mainly reported in primary prevention 
studies, we focused on the potential prognostic role of high Lp(a) levels on 
ACS in patients with advanced atherosclerosis. A systematic review of 
secondary prevention studies recently confirmed a weak, but still significant 
association between Lp(a) levels and future CV events [10].  
However, when considering cerebrovascular events, no significant 
association between elevated Lp(a) levels and recurrent stroke or transient 
ischemic attack was found [24]. This is in line with results of the 
Atherosclerosis Risk in Communities (ARIC) study [25], showing that 
elevated Lp(a) levels were mainly associated with an increased risk of CAD, 
but not of stroke. Another relevant issue of our study is represented by the 
identification of pathologic ranges of serum Lp(a) levels in patients with 
advanced atherosclerotic burden [13]. Also, due to different methods of 
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measurement, Lp(a) cut-off values are quite heterogeneous in current 
publications [26]. For instance, Lp(a) levels ranging from 10 to 77 mg/dL 
were indicated to predict cardiovascular events [10, 19, 23]. In our study 
investigating patients with severe carotid stenosis, we focused on the lowest 
Lp(a) level (10 mg/dL) reported as a potential cut-off value, in order to assess 
the prognostic accuracy of this parameter to predict ACS. This selection 
allowed us to demonstrate that Lp(a) levels above 10 mg/dL were predictive 
of the development of ACS at two-year follow-up. These data may suggest to 
use a quite low cut off level for Lp(a) in patients with advanced atherogenesis. 
Considering carotid intraplaque characteristics, no difference was found 
between patients with the high and low serum levels of Lp(a). 
Furthermore, only a weak positive association between serum Lp(a) levels 
and intraplaque SMC content in upstream regions was found, suggesting no 
strong association of  Lp(a) concentrations and intraplaque inflammation. Our 
results are in line with previous evidence of a modest impact of Lp(a) levels 
on carotid plaque morphology. For instance, no association between the Lp(a) 
and carotid intima-media thickness (IMT) in different populations was 
reported [27-31]. These observations indicate a high heterogeneity of 
atherosclerotic plaques at different arterial districts (i.e. carotid vs coronary 
atherosclerotic plaques). Evidence from the present investigation and other 
translational studies may support a specific role for Lp(a) in coronary rather 
than carotid atherosclerosis [32]. Clinical interventional studies with Lp(a) 
lowering treatments potentially reducing coronary events are needed to 
corroborate our observation further.  The present study has some limitations.  
Firstly, we performed a pilot study in which the cut-off value of Lp(a) was  
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selected from recently published clinical studies [19]. Therefore, we risked to 
miss significant differences between groups due to potential low study power. 
Secondly, although the Lp(a) measurement was obtained using an isoform-
insensitive nephelometry assay, we did not assess apoprotein(a) isoforms. 
Apoprotein(a) size isoforms are inversely correlated with Lp(a) concentration 
and low-molecular-weight apo(a) patterns have been reported as independent 
risk factors for atherosclerosis [11, 33]. Therefore, the evaluation of the 
apo(a) genotype would have allowed to better understand the potential 
biological relation of Lp(a) and ACS. Thirdly, given the little number of 
outcomes, the predictive model of Lp(a) for 24 months ACS could be adjusted 
only with a limited number (n=3) of independent variables.  
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CONCLUSIONS 
In conclusion, we showed that a low cut-off level of Lp(a) concentration  ≥10 
mg/dL can predict an ACS event in high CVD risk population with severe 
carotid atherosclerosis. Despite the potential low study power, these data may 
suggest to use a quite low cut-off level for Lp(a) in patients with advanced 
atherogenesis. When the histological parameters of the carotid plaques were 
taken into account, we did not find a  difference between patients with the 
high and low serum levels of Lp(a).  The weak positive association between 
Lp(a) levels and intraplaque SMC that our data highlighted suggest no strong 
association of Lp(a) concentrations and intraplaque inflammation. Our results 
are in line with others translational studies, indicating a high heterogeneity of 
atherosclerotic plaques at different vascular districts, supporting the 
hypothesis of a specific role for Lp(a) in coronary rather than carotid 
atherosclerosis. 
Finally, there are currently no approved pharmacologic therapies that 
specifically target lipoprotein(a). Despite this, preclinical [34, 35] as well as 
phase I and phase II studies on antisense oligonucleotides inhibiting the 
production of the apolipoprotein(a) in the hepatocyte [36-38],  showed a 
reduction of Lp(a) levels till 80% in patients who had established 
cardiovascular disease [38]. Hence, our results might be interesting to define 
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